Alector, Inc. (ALEC) stock
Close on Nov 12, 2026Market cap $273.56MP/E 7.0Yield –
Alector, Inc. grew revenue 151.2% to $173.47M over the twelve months to Sep 30, 2026. Free cash flow was -$150.02M. At the latest close the market valued the company at $273.56M, 7.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $273.56M
- P/E ratio
- 7.0
- Price to sales
- 1.58
- Price to book
- 2.35
- Dividend yield
- –
- Free cash flow yield
- -54.84%
Fundamentals
- Revenue
- $173.47M
- Net income
- $41.41M
- EPS, diluted
- $0.35
- Free cash flow
- -$150.02M
- Book value per share
- $1.04
- Diluted shares
- 112M
Trading
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Previous close
- $2.63
- Open
- $2.66
- Day's range
- $2.39 – $2.66
- Volume
- 1,872,048
- Average volume (20 days)
- 2,150,960
- Index membership
- Russell 2000, Russell 3000 (since Nov 2025)
- Beta (5 years)
- 1.51
- 52-week range
- $1.09 – $2.84
- RSI (14 days)
- 67.5
- Volatility (1 year)
- 84.1%
- Relative volume
- 1.33×
- WACC
- 12.4%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALEC | S&P 500 | Difference | ALEC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +17.8% | -2.7% | +20.5 pts | ||
| 3 months | +14.0% | -1.7% | +15.7 pts | ||
| Year to date | +57.1% | +11.9% | +45.2 pts | ||
| 1 year | +82.8% | +12.0% | +70.9 pts | ||
| 3 years | -45.6% | +78.2% | −123.7 pts | -18.3% | +21.2% |
| 5 years | -89.4% | +73.2% | −162.7 pts | -36.2% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alector filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- Results
About Alector
Biological Products, (No Diagnostic Substances)
Alector, Inc. is a clinical-stage biotechnology company that discovers and develops therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The company utilizes its proprietary blood-brain barrier delivery technology, called Alector Brain Carrier, to transport antibodies, enzymes, and siRNA molecules into the central nervous system. Its clinical pipeline features nivisnebart, an investigational antibody undergoing clinical evaluation for early Alzheimer's disease in collaboration with GlaxoSmithKline. Preclinical candidates include an anti-amyloid beta antibody, an enzyme replacement therapy, and genetic therapies targeting tau, alpha-synuclein, and NLRP3. As a clinical-stage biopharmaceutical enterprise without commercialized therapies, its primary partners are pharmaceutical companies rather than commercial end customers.
Company profile, executives and historyAlector stock: common questions
What is Alector's stock price?
ALEC closed at $2.45 on Nov 12, 2026, down 6.84% on the day. Over the past 52 weeks it traded between $1.09 and $2.84.
What is Alector's market cap?
Alector was worth $273.56M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ALEC's P/E ratio?
ALEC trades at 7.0 times earnings, based on diluted earnings per share of $0.35 over the twelve months to Sep 30, 2026.
How much revenue does Alector make?
Alector reported revenue of $173.47M for the twelve months to Sep 30, 2026, up 151.2% from a year earlier.
Does Alector pay a dividend?
No. Alector has not paid a cash dividend over the last twelve months.
When does Alector report earnings next?
Alector is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ALEC stock performed over the past year?
Including dividends, ALEC returned +82.8% over the past year, against +12.0% for the S&P 500.
How many ALEC shares are sold short?
8M shares were sold short at the latest FINRA report, 8.32% of the float, or 3.6 days of average trading volume.
Who are Alector's competitors?
Companies most similar to Alector by business, industry and size include RGNX, MAZE, VYGR, AGEN, FDMT.
See a number that looks wrong?